Mandate

Vinge advises Fouriertransform in connection investment in El-Forest

July 06, 2010

Vinge has advised Fouriertransform in connection with its investment in El-Forest. El-Forest has developed the world’s first forestry machine that uses energy efficient electric-hybrid technology. The technology gives rise to several environmental improvement measures. The investment is taking place through a directed new share issue pursuant to which Fouriertransform will become the largest individual shareholder. El-Forest’s forestry machine has a unique and patented track following and hybrid operation system which reduces fuel consumption, carbon dioxide emissions and reduces damage to forests due to the light weight of the machine.

Fouriertransform is a state-owned venture capital company which commercially supports innovative companies and entrepreneurs who can contribute to stimulating the Swedish vehicle industry.

Fouriertransform was represented in the negotiations by partner Bo Adrianzon and associate Johan Steen. Associates Sofia Berg and Adam Weissbach (IP) assisted in the due diligence phase.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024